Search Results
Imugene Licenses Potential for First “Allo” CAR T to be Approved in Blood Cancer
Imugene: A worldwide license to attack blood cancer
Imugene Investor Webinar | Acquisition of License for Azer-Cel Cell Therapy
Imugene secures IND approval for first-in-class onCARlytics trial
First Patient dosed in Imugene's PD1-Vaxx Combination Trial
IMU & RenovoRx announce collaboration
PBCAR0191 allo-CAR-T for ALL and NHL: preliminary findings
Imugene thrilled as first patient dosed in Phase 1 OASIS trial
Stocks of the Hour: AML3D, Imugene, Loyal Lithium
Imugene Investor Presentation | Non-deal Roadshow 2023 Australia
Kymriah Therapy at Roger Williams Cancer Center
Investor Presentation: CEO Leslie Chong at the 2023 NWR Virtual Healthcare Conference
